Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
New global clinical trial aims to replicate the mysterious “Mississippi baby” success

Researchers plan to identify 54 HIV-positive infants and treat them with standard antiretroviral drugs, beginning treatment within 48 hours of birth. The team plans to enroll HIV-positive infants across 17 hospitals and clinics in the U.S. and 11 other countries, including Haiti, India, Malawi, South Africa and Thailand.

Published
18 June 2014
From
Scientific American
South Africa: Antiretrovirals Credited for TB Decline

South Africa is seeing about 79,000 fewer TB cases annually thanks to increased HIV treatment uptake, according to the latest research from the National Institute for Communicable Diseases (NCID)

Published
13 June 2014
From
Health-e
Glaxo's ViiV Joins J&J's Janssen to Develop Single-Pill HIV Drug

Glaxo’s majority-owned ViiV Healthcare venture is collaborating with Johnson & Johnson’s Janssen unit to test a pill combining ViiV’s Tivicay with Janssen’s Edurant, ViiV said today in a statement. Trials are expected to begin next year, the Brentford, U.K.-based company said.

Published
13 June 2014
From
Bloomberg
PrEP users say it provides an 'extra layer of protection' and 'peace of mind'

American gay men who have chosen to take pre-exposure prophylaxis (PrEP) are aware of their own risk of being exposed to HIV and see PrEP as providing

Published
12 June 2014
By
Roger Pebody
Paper explores new theory on spread of HIV by "popular" cells

"Popular" cells - could there really be such a thing? According to a new opinion paper published in PLoS Pathogens, the human body may contain cells that have more contact with other cells and could be "superspreaders" of the HIV virus.

Published
11 June 2014
From
HIV / AIDS News From Medical News Today
Researchers trace HIV adaptation to its human host

In a new study that traces the evolution of HIV in North America, researchers have found evidence that the virus is slowly adapting over time to its human hosts. However, this change is so gradual that it is unlikely to have an impact on vaccine design.

Published
11 June 2014
From
Science Daily
Novel approach found to reactivate latent HIV

A team of scientists at the Gladstone Institutes has identified a new way to make latent HIV reveal itself, which could help overcome one of the biggest obstacles to finding a cure for HIV infection.

Published
10 June 2014
From
HIV / AIDS News From Medical News Today
People starting therapy on a boosted protease inhibitor don't need to switch after one virological failure episode, study indicates

Remaining on the same regimen is a “reasonable” strategy for people taking first-line antiretroviral therapy (ART) based on a ritonavir-boosted protease inhibitor who experience virologic failure, according to

Published
09 June 2014
By
Michael Carter
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.

Published
06 June 2014
From
Merck
AAHIVM, AGS, and ACRIA release updated recommendations for older patients with HIV

The American Academy of HIV Medicine (AAHIVM), ACRIA, and the American Geriatrics Society (AGS) this week announced a major update to its 2011 report, Recommended Treatment Strategies for Clinicians Managing Older Patients with HIV. Revised topics include assessing functional capacity, smoking cessation, and management of diabetes, COPD, osteoporosis, and hypertension.

Published
06 June 2014
From
EATG

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.